SSK1

3 papers6 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

2 independent labs in 3 countries

Funders: Beijing Tongren Hospital and others

Animals3

Outcomes

pre-B colony formation

downin mice1

1 study

SSK1 decreases pre-B colony formation in mice.
“observed reduced pre-B colony formation after SSK1 treatment.”
Animalsin Lin-Sca1+ immature population from Sca1-E::R transgenic mice
Targeting oncogene-induced senescence in ETV6::RUNX1 pre-leukemic cells
Cell death discovery11 Mar 2026

Senescent cell survival

downin mouse cells1

1 study

SSK1 decreases senescent cell survival in mouse cells.
“Senolytics SSK1 and piperlongumine selectively eliminated E::R+ cells by exploiting elevated β-gal activity and ROS levels, respectively.”
Cellsin E::R+ cells
Targeting oncogene-induced senescence in ETV6::RUNX1 pre-leukemic cells
Cell death discovery11 Mar 2026

Extracellular matrix remodelling

upin mice1

1 study

SSK1 improves extracellular matrix remodelling in mice.
“enhanced retention of ECM, and remodelled subchondral bone homeostasis in both young and aged ACLT-induced OA murine model”
AnimalsACLT-induced OAintra-articular injectionjointevery 3 daysmales
β-galactosidase-targeted senolytic prodrug ameliorates preclinical models of post-traumatic osteoarthritis
EBioMedicine6 Nov 2025

More on Extracellular matrix remodelling

Pain response

upin mice1

1 study

SSK1 improves pain response in mice.
“Intra-articular administration of SSK1 showed improved pain response”
AnimalsACLT-induced OAintra-articular injectionjointevery 3 daysmales
β-galactosidase-targeted senolytic prodrug ameliorates preclinical models of post-traumatic osteoarthritis
EBioMedicine6 Nov 2025

Senescence-associated secretory phenotype (SASP)

downin human cells1

1 study

SSK1 prevents senescence-associated secretory phenotype (SASP) in human cells.
“senolytic SSK1 prevented the generation of senescence-associated secretory phenotype factors”
Cellsin vitro co-culturecartilage
β-galactosidase-targeted senolytic prodrug ameliorates preclinical models of post-traumatic osteoarthritis
EBioMedicine6 Nov 2025

More on Senescence-associated secretory phenotype (SASP)

Senescent chondrocytes

downin human cells1

1 study

SSK1 decreases senescent chondrocytes in human cells.
“SSK1 showed precise, efficient, and broad-spectrum elimination of senescent chondrocytes.”
Cellsin vitrocartilage
β-galactosidase-targeted senolytic prodrug ameliorates preclinical models of post-traumatic osteoarthritis
EBioMedicine6 Nov 2025